NASDAQ:OPTN - OptiNose Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $26.62 -0.28 (-1.04 %) (As of 07/18/2018 08:18 AM ET)Previous Close$26.90Today's Range$26.2650 - $27.365052-Week Range$15.01 - $30.00Volume110,741 shsAverage Volume314,460 shsMarket Capitalization$1.02 billionP/E Ratio-4.73Dividend YieldN/ABetaN/A Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania. Receive OPTN News and Ratings via Email Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:OPTN CUSIPN/A Webwww.optinose.com Phone267-364-3500 Debt Debt-to-Equity Ratio0.57 Current Ratio9.66 Quick Ratio9.50 Price-To-Earnings Trailing P/E Ratio-4.73 Forward P/E Ratio-8.45 P/E GrowthN/A Sales & Book Value Annual Sales$47.50 million Price / Sales21.30 Cash FlowN/A Price / CashN/A Book Value$4.09 per share Price / Book6.51 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees82 Outstanding Shares38,010,000Market Cap$1,022.38 OptiNose (NASDAQ:OPTN) Frequently Asked Questions What is OptiNose's stock symbol? OptiNose trades on the NASDAQ under the ticker symbol "OPTN." How were OptiNose's earnings last quarter? OptiNose Inc (NASDAQ:OPTN) issued its earnings results on Monday, May, 14th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.07. The business had revenue of $0.87 million for the quarter. View OptiNose's Earnings History. What price target have analysts set for OPTN? 4 brokerages have issued 1-year price objectives for OptiNose's shares. Their predictions range from $27.00 to $34.00. On average, they anticipate OptiNose's stock price to reach $30.75 in the next year. This suggests a possible upside of 15.5% from the stock's current price. View Analyst Ratings for OptiNose. What is the consensus analysts' recommendation for OptiNose? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of OptiNose's key competitors? Some companies that are related to OptiNose include Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), The Medicines (MDCO), Blueprint Medicines (BPMC), Amicus Therapeutics (FOLD), Ascendis Pharma A/S (ASND), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Supernus Pharmaceuticals (SUPN), Emergent Biosolutions (EBS), Portola Pharmaceuticals (PTLA) and Akcea Therapeutics (AKCA). Who are OptiNose's key executives? OptiNose's management team includes the folowing people: Mr. Peter K. Miller, CEO & Director (Age 57)Dr. Ramy A. Mahmoud M.D., M.P.H., Pres& COO (Age 53)Mr. Keith Alan Goldan, Chief Financial Officer (Age 47)Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 42)Mr. Thomas E. Gibbs, Chief Commercial Officer (Age 46) When did OptiNose IPO? (OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO. Has OptiNose been receiving favorable news coverage? News headlines about OPTN stock have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OptiNose earned a news sentiment score of 0.16 on Accern's scale. They also assigned press coverage about the company an impact score of 46.49 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. How do I buy shares of OptiNose? Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OptiNose's stock price today? One share of OPTN stock can currently be purchased for approximately $26.62. How big of a company is OptiNose? OptiNose has a market capitalization of $1.02 billion and generates $47.50 million in revenue each year. The company earns $-48,900,000.00 in net income (profit) each year or ($5.63) on an earnings per share basis. OptiNose employs 82 workers across the globe. How can I contact OptiNose? OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected] MarketBeat Community Rating for OptiNose (NASDAQ OPTN)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 84 (Vote Outperform)Underperform Votes: 106 (Vote Underperform)Total Votes: 190MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What are Closed-End Mutual Funds?